Lectin-based diagnostics of cancers
AssigneeKaivogen Oy
InventorsKamlesh GIDWANI, Kim PETTERSSON, Henna KEKKI
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to non-invasive diagnostics of cancers, such as breast cancer, colorectal cancer, pancreatic cancer and prostate cancer, on the basis of altered glycosylation patterns of cancer-associated biomarkers.
Claims37
A method of determining a prostate cancer disease state in a subject, said method comprising:
- assaying a sample obtained from said a subject for detecting a level of a PSA glycoform which binds to macrophage galactose-type lectin (MGL);
- comparing a detected level of said lectin-binding PSA glycoform in said sample with that of a control sample or a predetermined threshold value;
- and
- determining a prostate cancer disease state for said subject based on said comparison.
A method of determining a colorectal cancer disease state in a subject, said method comprising:
- assaying a sample obtained from a subject for detecting a level of a CEA glycoform which binds to one or more lectins selected from a group consisting of mannose binding lectin (MBL), Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) and MGL;
- comparing the detected level of said lectin-binding CEA glycoform in said sample with that of a control sample or a predetermined threshold value, and
- determining a colorectal cancer disease state for said subject based on said comparison.
A method of determining a pancreatic cancer disease state in a subject, said method comprising:
- assaying a sample obtained from a subject for detecting a level of a CA19-9 glycoform which binds to DC-SIGN;
- comparing the detected level of said lectin-binding CA19-9 glycoform in said sample with that of a control sample or a predetermined threshold value;
- and
- determining a prostate cancer disease state for said subject based on said comparison.
A method of determining a breast cancer disease state in a subject, said method comprising:
- assaying a sample obtained from a subject for detecting a level of CA15-3 glycoform which binds to one or more lectins selected form the group consisting of MGL and wheat germ agglutin (WGA);
- comparing the detected level of said lectin-binding glycoform of CA15-3 in said sample with that of a control sample or a predetermined threshold value;
- and
- determining a breast cancer disease state for said subject based on said comparison.
A kit for determining a prostate cancer disease state in a subject, the kit, comprising:
- a PSA-binding agent and MGL;
- wherein either said PSA-binding agent or said MGL includes a detectable label.
A kit for determining a colorectal cancer disease state in a subject, the kit, comprising:
- a CEA-binding agent and one or more lectins selected from the group consisting of MBL, DC-SIGN and MGL;
- wherein either said CEA-binding agent or said lectin includes a detectable label.
A kit for determining a pancreatic cancer disease state in a subject, the kit, comprising:
- a CA19-9-binding agent and DC-SIGN;
- wherein either said CA19-9-binding agent or said DC-SIGN includes a detectable label.
A kit for determining a breast cancer disease state in a subject, the kit comprising:
- a CA15-3-binding agent;
- and
- one or more lectins selected from the group consisting of MGL and WGA;
- wherein either said CA15-3-binding agent or said one or more lectins includes a detectable label.
A method for determining a prostate cancer disease state in a subject, the method comprising:
- assaying a sample obtained from said subject for a level of PSA glycoform which binds to MGL.
A method for determining a colorectal cancer disease state in a subject, the method comprising:
- assaying a sample obtained from said subject for a level of CEA glycoform which binds MBL, DC-SIGN and/or MGL.
A method for determining a pancreatic cancer disease state in a subject, the method comprising:
- assaying a sample obtained from said subject for a level of CA19-9 glycoform which binds to DC-SIGN.
A method for determining a breast cancer disease state in a subject, the method comprising:
- assaying a sample obtained from said subject for a level of CA15-3 glycoform which binds to MGL, WGA, DSL, and/or Gal4, each alone or in any combination thereof.
Dependencies are inferred from the claim text.